↑ 疾患リストへ ← 戻る

 159. 色素性乾皮症 [臨床試験数:4,薬物数:8(DrugBank:2),標的遺伝子数:1,標的パスウェイ数:1] 

Searched query = "Xeroderma pigmentosum"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-022968-13-ES22/03/201119 March 2012Estudio clínico de fase II, multicéntrico, abierto de trabectedina (Yondelis®) en pacientes con cáncer de mama avanzado, HER2 negativo, positivo para receptores hormonales, con sobreexpresión o subexpresión del gen xeroderma pigmentosum de clase G (XPG).Estudio clínico de fase II, multicéntrico, abierto de trabectedina (Yondelis®) en pacientes con cáncer de mama avanzado, HER2 negativo, positivo para receptores hormonales, con sobreexpresión o subexpresión del gen xeroderma pigmentosum de clase G (XPG).Cáncer de mama avanzado.
MedDRA version: 13 Level: LLT Classification code 10006204 Term: Carcinoma de mama
Trade Name: YONDELIS 0,25 mg polvo para concentrado para solución para perfusión
Pharmaceutical Form: Powder for solution for infusion
INN or Proposed INN: TRABECTEDINA
Other descriptive name: TRABECTEDINA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.25-
Trade Name: YONDELIS 1 mg polvo para concentrado para solución para perfusión
Pharmaceutical Form:
INN or Proposed INN: TRABECTEDINA
Other descriptive name: TRABECTEDINA
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
PharmaMar S.A. Sociedad UnipersonalAuthorisedFemale: yes
Male: no
100Spain
2EUCTR2010-022968-13-BE16/03/201121 August 2017Study of the medicinal product Trabectedin in Patients with Advanced Breast Carcinoma.Multicenter, Open-Label, Phase II Study of Trabectedin (Yondelis®) in Patients with Hormonal Receptors Positive, HER2 Negative, Advanced Breast Carcinoma, Overexpressing or Underexpressing Xeroderma Pigmentosum G Gene (XPG)Advanced Breast Carcinoma
MedDRA version: 14.0 Level: LLT Classification code 10006204 Term: Breast carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
Trade Name: Yondelis 0.25 mg powder for concentrate for solution for infusion.
Pharmaceutical Form: Powder for concentrate for solution for infusion
INN or Proposed INN: trabectedine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.25-
Trade Name: Yondelis 1 mg powder for concentrate for solution for infusion.
Pharmaceutical Form: Powder for concentrate for solution for infusion
INN or Proposed INN: trabectedine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharma Mar, S.A. Sociedad UnipersonalNot RecruitingFemale: yes
Male: yes
100Phase 2Belgium;Spain
3NCT00002811July 199619 February 2015T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma PigmentosumA RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSESPrecancerous ConditionDrug: liposomal T4N5 lotionApplied GeneticsNot recruiting2 Years60 YearsBoth30Phase 3United States;Germany;United Kingdom
4NCT00025012June 199119 February 2015Isotretinoin in Preventing Skin CancerUse Of Isotretinion For Prevention Of Skin Cancer In Patients With Xeroderma Pigmentosum Or Nevoid Basal Cell Carcinoma SyndromeMelanoma (Skin);Non-melanomatous Skin CancerDrug: isotretinoinNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Not recruiting2 YearsN/ABothN/AUnited States